CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase with IC50 of 16 nM.
CC-223 displays >200-fold selectivity over the related PI3K-α (IC50=4.0 uM), shows no significant inhibition of ATR or SMG1 and weakly inhibits DNA-PK (IC50=0.84 uM).
CC-223 inhibits mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems, exhibits growth inhibitory activity in hematologic and solid tumor cell lines.
CC-223 demonstrates tumor growth inhibition in multiple solid tumor xenografts.
